Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q5VWP2

UPID:
TET5C_HUMAN

ALTERNATIVE NAMES:
Non-canonical poly(A) polymerase FAM46C

ALTERNATIVE UPACC:
Q5VWP2; A3KMG2; Q8NE25; Q9NXK0

BACKGROUND:
The protein Terminal nucleotidyltransferase 5C, alternatively named Non-canonical poly(A) polymerase FAM46C, is pivotal in enhancing mRNA stability and gene expression. It achieves this by transferring adenosine molecules from ATP to the mRNA poly(A) tail, a process that is crucial for the stability and expression of mRNAs, particularly those encoding proteins destined for the endoplasmic reticulum. Moreover, it has a role in aiding the replication of certain viruses, such as the yellow fever virus, by responding to type I interferon.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Terminal nucleotidyltransferase 5C offers a promising avenue for developing novel therapeutic approaches, particularly in the realms of viral replication control and the modulation of gene expression for proteins targeting the endoplasmic reticulum.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.